Copolymer-1 (Cop-1) improves neurological recovery after middle cerebral artery occlusion in rats

被引:24
作者
Ibarra, Antonio
Avendano, Hector
Cruz, Yolanda
机构
[1] Unidad Invest Med Enfermedades Neurol, HE, CMN Siglo XXI, IMSS, Mexico City 06720, DF, Mexico
[2] Proyecto CAMINA AC, Mexico City 14050, DF, Mexico
关键词
copaxone; focal cerebral ischemia; glatiramer acetate; middle cerebral artery occlusion; neuroprotection; protective autoimmunity;
D O I
10.1016/j.neulet.2007.08.038
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The damage in ischemic stroke is caused by two events: (i) the ischemic phenomenon by itself; (ii) the self-destructive mechanisms developed as a consequence of ischemia. The inflammatory response is one of these destructive phenomena that accompanies and exacerbates the developing injury. Since it has been suggested that immune cells participate in neuroprotective and restorative processes, modulation rather than elimination of this inflammatory response could be a strategy to improve the neurological outcome. The immune modulator copolymer-1 (Cop-1), a synthetic basic random copolymer of amino acids, is a potent inducer of Th2 regulatory cells which, aside from exerting modulatory actions, is capable of releasing neurotrophic factors. There is evidence that Cop-1-specific T cells exert neuroprotective and even restorative effects in diverse neurodegenerative diseases. In order to test the ability of Cop-1 to prevent ischemic injury in a model of transient middle cerebral artery (MCA) occlusion, two groups of rats were treated either with Cop-1 or with saline solution (SS). Seven days after occlusion, Cop-1 treated rats presented a significant improvement in neurological function compared to SS-treated animals (1.2 +/- 0.4 and 2.8 +/- 0.5 mean S.D., respectively; p = 0.008). Histological findings showed that the percentage of infarct volume was smaller in Cop-1 treated rats (4.8 +/- 1.5), in comparison with those receiving SS (32.2 +/- 8.6; p = 0.004). Cop-1 constitutes a promising therapy for stroke; thereby, the enforcement of further experimental investigation is encouraged in order to be able to formulate the best strategy. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:110 / 113
页数:4
相关论文
共 24 条
[1]   The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice [J].
Aharoni, R ;
Eilam, R ;
Domev, H ;
Labunskay, G ;
Sela, M ;
Arnon, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (52) :19045-19050
[2]   Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ [J].
Aharoni, R ;
Kayhan, B ;
Eilam, R ;
Sela, M ;
Arnon, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (24) :14157-14162
[3]   Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis [J].
Angelov, DN ;
Waibel, S ;
Guntinas-Lichius, O ;
Lenzen, M ;
Neiss, WF ;
Tomov, TL ;
Yoles, E ;
Kipnis, J ;
Schori, H ;
Reuter, A ;
Ludolph, A ;
Schwartz, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (08) :4790-4795
[4]   Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications [J].
Arnon, R ;
Aharoni, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 :14593-14598
[5]   Immunomodulation by the copolymer glatiramer acetate [J].
Arnon, R ;
Sela, M .
JOURNAL OF MOLECULAR RECOGNITION, 2003, 16 (06) :412-421
[6]   New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis [J].
Arnon, R ;
Sela, M ;
Teitelbaum, D .
JOURNAL OF NEUROLOGY, 1996, 243 (04) :S8-S13
[7]   Vaccination with autoantigen protects against aggregated β-amyloid and glutamate toxicity by controlling microglia:: effect of CD4+CD25+ T cells [J].
Avidan, H ;
Kipnis, J ;
Butovsky, O ;
Caspi, RR ;
Schwartz, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (12) :3434-3445
[8]   Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma [J].
Bakalash, S ;
Kessler, A ;
Mizrahi, T ;
Nussenblatt, R ;
Schwartz, M .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (08) :3374-3381
[9]   Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease [J].
Benner, EJ ;
Mosley, RL ;
Destache, CJ ;
Lewis, TB ;
Jackson-Lewis, V ;
Gorantla, S ;
Nemachek, C ;
Green, SR ;
Przedborski, S ;
Gendelman, HE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (25) :9435-9440
[10]   Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1 [J].
Butovsky, Oleg ;
Koronyo-Hamaoui, Maya ;
Kunis, Gilad ;
Ophir, Eran ;
Landa, Gennady ;
Cohen, Hagit ;
Schwartz, Michal .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (31) :11784-11789